BioPharmX Announces Last Patient Visit in Phase 2b Trial of BPX-04 for Papulopustular Rosacea
SAN JOSE, Calif., May 22, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, announced today that the last patient in the Company's Phase 2b clinical trial of BPX-041, a novel topical